Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild-to-moderate psoriasis.
Saved in:
| Title: | Phase 1 study of balinatunfib, an oral inhibitor of TNFR1 signal in mild-to-moderate psoriasis. |
|---|---|
| Authors: | Nassr N; Sanofi, Frankfurt, Germany., Chow OA; Sanofi, Cambridge, Massachusetts, USA., Nguyen MA; Sanofi, Frankfurt, Germany., Perrin L; Sanofi, Montpellier, France., Schumacher F; Sanofi, Frankfurt, Germany., Wagner FD; Charité Research Organisation, Berlin, Germany., Dreis C; Sanofi, Frankfurt, Germany., Lahmar A; Sanofi, Morristown, New Jersey, USA., Kohlmann M; Sanofi, Frankfurt, Germany., Wiekowski M; Sanofi, Morristown, New Jersey, USA., Matos TR; Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands.; Sanofi, Amsterdam, Netherlands. |
| Source: | Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2026 Jun; Vol. 40 (6), pp. 1030-1039. Date of Electronic Publication: 2026 Feb 11. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9216037 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3083 (Electronic) Linking ISSN: 09269959 NLM ISO Abbreviation: J Eur Acad Dermatol Venereol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1468-3083 |
|---|---|
| DOI: | 10.1111/jdv.70262 |
